iCAD, Inc. announced a strategic partnership with Densitas, Inc. The partnership enables breast imaging centers and radiologists to provide end-to-end breast health care that ensures every aspect of a woman?s breast health journey is addressed, starting from the first step of quality screening mammograms and extending through breast cancer detection, breast density assessment, and a comprehensive evaluation of breast cancer risk. Densitas offers a robust and comprehensive mammography quality assurance platform, comprised of intelliMammo® and intelliMaven?. IntelliMammo® is built on deep learning and machine learning algorithms that assess clinical image quality and breast density that are the foundation for advanced analytics, continuous quality control, efficient workflows and remote quality oversight.

In an industry-first move, intelliMaven? is a GPT AI application engineered to streamline workflows, deliver on-demand expert feedback, and foster a culture of confidence and autonomy among technologists. The integrated platform delivers a scalable, sustainable quality assurance system tailored for mammography facilities to maximize operational efficiency, optimize compliance with the FDA Mammography Quality Standards Act (MQSA) EQUIP, and meet ACR accreditation standards.

The platform empowers facilities to maximize resource allocation and focus on activities that drive the most value. With iCAD?s AI-enabled ProFound Breast Health Suite, offering clinically proven solutions for cancer detection, density assessment, and personalized risk evaluation, medical professionals will have a more well-rounded set of data on each patient?s breast health. Clinical studies have demonstrated that the use of iCAD?s ProFound AI solutions can significantly improve reading sensitivity and specificity and reduce reading times, thus enhancing clinical decision support and workflow efficiency for radiologists.

ProFound Breast Health Suite: ProFound AI offers clinically proven time-saving benefits to radiologists, including reducing reading time by 52.7%, thereby halving the time it takes radiologists to read 3D mammography datasets. ProFound AI for DBT improved radiologist sensitivity by 8% and reduced unnecessary patient recall rates by 7.2%. The ProFound Risk platform has a proven track record of predicting the risk of breast cancer 2.4x more accurately in the next year than traditional lifetime risk models.

iCAD?s ProFound Density Assessment uses mammography images to categorize breast density, leading to personalized patient care plans with supplemental screenings and a custom schedule. IntelliMammo® AI Mammography Quality Platform: IntelliMammo® reduces clinical image quality error rates by as much as 44%, and streamlines compliance with key MQSA EQUIP and adherence to ACR accreditation requirements, quality assurance and oversight tasks in mere seconds and minutes, as opposed to days and weeks. IntelliMaven?

is designed to increase radiological technologists? clinical confidence and autonomy, and to limit interruptions to radiologists when reading exams. IntelliMammo® densityAI? breast density has been clinically validated to have a strong association with breast cancer risk, providing a practical automated method for risk stratification.